Suchen Sie nach Informationen zu Novartis-Konzernzentrale? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
https://www.novartis.com/
Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma. October 26, 2021. Media Release. Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz.
https://www.novartis.com/de-de/karriere/unsere-standorte
Unsere Standorte. Wir sind einer der führenden Innovatoren des deutschen Gesundheitssystems und ein strategischer Pfeiler der Versorgung. Mit zehn Standorten in sechs Bundesländern tragen wir zur Novartis Vision bei, das Leben von Menschen heute und in Zukunft zu verbessern.
https://www.novartis.com/news/media-releases/novartis-announces-new-organizational-structure-accelerate-growth-strengthen-pipeline-and-increase-productivity
Novartis expects value creation through these operational improvements, ensuring at least 4% sales growth (CAGR 2020-2026 in cc*), and delivering high end of the company’s IM margin guidance of high 30s in the medium term and 40%+ in the mid- to long-term Company also announces changes to the Executive Committee of Novartis (ECN):
https://www.campus.novartis.com/en/novartis-pavillon/plan-your-visit-novartis-pavillon
Everything you need to know to make your visit as smooth and enjoyable as possible. Eye-opening science, thought-provoking ideas and beautiful surroundings – your visit to Novartis Pavillon will be a trip to remember. Plan ahead with information on travel, accessibility, food and drink, services and more.
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Novartis-Konzernzentrale gefunden haben.
